Cellebrite clarifies equity plan dilution at 9.2% after shareholder inquiries

Cellebrite issued a Form 6-K clarification on dilution figures in its 2026 annual meeting proxy statement.

• As of Aug. 1, 2026, 251,341,060 shares were outstanding; 25,554,161 shares were reserved for equity plans.
• Fully diluted shares totaled 276,895,221, implying potential dilution of about 9.2%.
• The share reserve reflected a 3,500,000-share reduction in the 2021 incentive plan pool, effective July 29, 2026.